艰难梭菌感染的临床抗菌药物治疗进展  

Advances in Clinical Antimicrobial Therapy of Clostridium Difficile Infection

作　　者：吕燕妮[1] 付龙生 宋小玲[1] 周芸[1] LYU Yanni;FU Longsheng;SONG Xiaoling;ZHOU Yun(The First Affiliated Hospital of Nanchang University,Nanchang Jiangxi 330006,China)

机构地区：[1]南昌大学第一附属医院,江西南昌330006

出　　处：《药品评价》2022年第16期1015-1018,共4页Drug Evaluation

摘　　要：艰难梭菌是抗菌药物相关性腹泻的主要原因,虽然抗菌药治疗是艰难梭菌感染的首选治疗方法,但目前有效的抗菌药种类相对较少。一些新型抗菌药,如卡达唑胺、苏洛霉素、利地尼唑已证明对艰难梭菌具有活性,其中一些已经被批准用于临床,或正在进行临床试验。在这篇综述中,将讨论艰难梭菌感染的当前和新兴临床抗菌药物治疗进展。Clostridium difficile is the main cause of antimicrobial associated diarrhea.Although antibiotic therapy is the preferred treatment for clostridium difficile infection,there are relatively few effective antibacterial drugs.Sone of the newer antimicrobials for clostridium difficile infection,such as kadazolamide,sulomycin,and lidenizole,which have been shown to be active against clostridium difficile,some of which have been approved for clinical use or are in clinical trials.In this review,we would discuss current and emerging clinical advances in antimicrobial therapy for clostridium difficile infection.

关 键 词：艰难梭菌 腹泻 万古霉素 甲硝唑 非达霉素 抗体 单克隆 

分 类 号：R978[医药卫生—药品]